AMP-Deoxynojirimycin (CAS 216758-20-2)
QUICK LINKS
AMP-Deoxynojirimycin (AMP-dNM) is a hydrophobic derivative of dNM that potently inhibits beta-glucosidase 2 (BGD, IC50 = 0.3 nM), less potently antagonizes glucosylceramide synthase (GCS, IC50 = 25 nM), and only poorly inhibits other GCase isoforms. The lipid messenger ceramide is converted to glucosylceramide by GCS. In the reverse direction, BGD cleaves the glucosyl moiety from glucosylceramide, liberating ceramide, which can be converted into sphingomyelin. AMP-Deoxynojirimycin may act to induce sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in Hep-G2 cells, strongly suppress inflammation in a murine model of hapten-induced colitis, and enhance insulin sensitivity in murine and rat models of insulin resistance.
AMP-Deoxynojirimycin (CAS 216758-20-2) References
- Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. | Aerts, JM., et al. 2003. Philos Trans R Soc Lond B Biol Sci. 358: 905-14. PMID: 12803924
- Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. | Shen, C., et al. 2004. Int Immunopharmacol. 4: 939-51. PMID: 15182733
- Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. | Aerts, JM., et al. 2007. Diabetes. 56: 1341-9. PMID: 17287460
- The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. | Bijl, N., et al. 2008. J Pharmacol Exp Ther. 326: 849-55. PMID: 18550691
- Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. | Casson, L., et al. 2013. PLoS One. 8: e54525. PMID: 23342165
- Rottlerin Stimulates Exosome/Microvesicle Release Via the Increase of Ceramide Levels Mediated by Ampk in an In Vitro Model of Intracellular Lipid Accumulation. | Molina, YL., et al. 2022. Biomedicines. 10: PMID: 35740338
- Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. | Overkleeft, HS., et al. 1998. J Biol Chem. 273: 26522-7. PMID: 9756888
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AMP-Deoxynojirimycin, 500 µg | sc-223780 | 500 µg | $111.00 | |||
AMP-Deoxynojirimycin, 1 mg | sc-223780A | 1 mg | $208.00 |